Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting.

Lim CS, Ko YK, Kim YH, Park SI, Kim JK, Kim MJ, Kim HJ.

Korean J Anesthesiol. 2013 Mar;64(3):212-7. doi: 10.4097/kjae.2013.64.3.212.

2.

A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.

Gan TJ, Apfel CC, Kovac A, Philip BK, Singla N, Minkowitz H, Habib AS, Knighton J, Carides AD, Zhang H, Horgan KJ, Evans JK, Lawson FC; Aprepitant-PONV Study Group..

Anesth Analg. 2007 May;104(5):1082-9, tables of contents.

PMID:
17456656
3.

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group..

Cancer. 2003 Jun 15;97(12):3090-8.

4.

Effects of ondansetron in the prevention of postoperative nausea and vomiting in children.

Ummenhofer W, Frei FJ, Urwyler A, Kern C, Drewe J.

Anesthesiology. 1994 Oct;81(4):804-10.

PMID:
7943830
5.

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.

Cancer. 2003 May 1;97(9):2290-300.

6.

Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery.

Diemunsch P, Gan TJ, Philip BK, Girao MJ, Eberhart L, Irwin MG, Pueyo J, Chelly JE, Carides AD, Reiss T, Evans JK, Lawson FC; Aprepitant-PONV Protocol 091 International Study Group..

Br J Anaesth. 2007 Aug;99(2):202-11.

8.

Aprepitant vs. multimodal prophylaxis in the prevention of nausea and vomiting following extended-release epidural morphine.

Hartrick CT, Tang YS, Hunstad D, Pappas J, Muir K, Pestano C, Silvasi D.

Pain Pract. 2010 May-Jun;10(3):245-8. doi: 10.1111/j.1533-2500.2010.00364.x.

PMID:
20230453
9.

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group..

J Clin Oncol. 2003 Nov 15;21(22):4112-9.

PMID:
14559886
10.

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.

Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.

Breast Cancer Res Treat. 2009 Feb;113(3):529-35. doi: 10.1007/s10549-008-9957-9.

PMID:
18327706
11.
12.
13.

Antiemetic efficacy of combined aprepitant and dexamethasone in patients at high-risk of postoperative nausea and vomiting from epidural fentanyl analgesia.

Kawano H, Matsumoto T, Hamaguchi E, Manabe S, Nakagawa M, Yamada A, Fujimoto M, Tada F.

Minerva Anestesiol. 2015 Apr;81(4):362-8.

PMID:
25220550
14.
16.

Comparison of ramosetron with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery.

Kim SI, Kim SC, Baek YH, Ok SY, Kim SH.

Br J Anaesth. 2009 Oct;103(4):549-53. doi: 10.1093/bja/aep209.

18.
19.

Comparison of ondansetron with ondansetron and dexamethasone in prevention of PONV in diagnostic laparoscopy.

Rajeeva V, Bhardwaj N, Batra YK, Dhaliwal LK.

Can J Anaesth. 1999 Jan;46(1):40-4.

PMID:
10078401
20.

Prospective application of a simplified risk score to prevent postoperative nausea and vomiting.

Rüsch D, Eberhart L, Biedler A, Dethling J, Apfel CC.

Can J Anaesth. 2005 May;52(5):478-84.

PMID:
15872125
Items per page

Supplemental Content

Support Center